Reduced Immunogenicity of Intraparenchymal Delivery of Adeno-Associated Virus Serotype 2 Vectors: Brief Overview

被引：3

作者：

Hwu, Wuh-Liang ^{[1
]}

Muramatsu, Shin-Ichi ^{[2
,3
]}

Gidoni-Ben-Zeev, Bruria ^{[4
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Med Genet & Pediat, 7 Chung Shan S Rd, Taipei, Taiwan

[2] Jichi Med Univ, Ctr Open Innovat, Div Neurol Gene Therapy, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan

[3] Univ Tokyo, Ctr Gene & Cell Therapy, Inst Med Sci, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1080071, Japan

[4] Tel Aviv Univ, Sackler Sch Med, Dept Pediat Neurol, IL-6997801 Tel Aviv, Israel

来源：

CURRENT GENE THERAPY | 2022年 / 22卷 / 03期

关键词：

Adeno-associated virus; aromatic L-amino acid decarboxylase deficiency; eladocagene exuparvovec; immunogenicity; vectors; rare disease; AMINO-ACID DECARBOXYLASE; CENTRAL-NERVOUS-SYSTEM; INNATE IMMUNE-RESPONSES; MEDIATED GENE-TRANSFER; OPEN-LABEL; PHASE-I; THERAPY; TRANSDUCTION; LIVER; AAV9;

D O I：

10.2174/1566523221666210922155413

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Pre existing immunity to adeno-associated virus (AAV) poses a concern in AAV vector-mediated gene therapy. Localized administration of low doses of carefully chosen AAV sero-types can mitigate the risk of an immune response. This article will illustrate the low risk of immune response to AAV serotype 2 vector-mediated gene therapy to the brain with support from clinical trial data in aromatic L-amino acid decarboxylase deficiency and Parkinson disease.

引用

页码：185 / 190

页数：6

共 56 条

[1] Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases? [J].

Bey, Karim ;

Deniaud, Johan ;

Dubreil, Laurence ;

Joussemet, Beatrice ;

Cristini, Joseph ;

Ciron, Carine ;

Hordeaux, Juliette ;

Le Boulc'h, Morwenn ;

Marche, Kevin ;

Maquigneau, Maud ;

Guilbaud, Michael ;

Moreau, Rosalie ;

Larcher, Thibaut ;

Deschamps, Jack-Yves ;

Fusellier, Marion ;

Blouin, Veronique ;

Sevin, Caroline ;

Cartier, Nathalie ;

Adjali, Oumeya ;

Aubourg, Patrick ;

Moullier, Philippe ;

Colle, Marie-Anne .

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2020, 17 :771-784

[2] Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents [J].

Calcedo, Roberto ;

Morizono, Hiroki ;

Wang, Lili ;

McCarter, Robert ;

He, Jianping ;

Jones, David ;

Batshaw, Mark L. ;

Wilson, James M. .

CLINICAL AND VACCINE IMMUNOLOGY, 2011, 18 (09) :1586-1588

[3] Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial [J].

Chien, Yin-Hsiu ;

Lee, Ni-Chung ;

Tseng, Sheng-Hong ;

Tai, Chun-Hwei ;

Muramatsu, Shin-ichi ;

Byrne, Barry J. ;

Hwu, Wuh-Liang .

LANCET CHILD & ADOLESCENT HEALTH, 2017, 1 (04) :265-273

[4] Safety and tolerability of putaminal AADC gene therapy for Parkinson disease [J].

Christine, C. W. ;

Starr, P. A. ;

Larson, P. S. ;

Eberling, J. L. ;

Jagust, W. J. ;

Hawkins, R. A. ;

VanBrocklin, H. F. ;

Wright, J. F. ;

Bankiewicz, K. S. ;

Aminoff, M. J. .

NEUROLOGY, 2009, 73 (20) :1662-1669

[5] Cerebral Infusion of AAV9 Vector-encoding Non-self Proteins Can Elicit Cell-mediated Immune Responses [J].

Ciesielska, Agnieszka ;

Hadaczek, Piotr ;

Mittermeyer, Gabriele ;

Zhou, Shangzhen ;

Wright, J. Fraser ;

Bankiewicz, Krystof S. ;

Forsayeth, John .

MOLECULAR THERAPY, 2013, 21 (01) :158-166

[6]

ClinicalTrials.gov, 2021, RGX 121 GEN THER PAT

[7]

ClinicalTrials.gov, 2021, GEN THER CHILDR VAR

[8]

ClinicalTrials.gov, 2020, RGX 111 GEN THER PAT

[9]

ClinicalTrials.gov, 2021, DOS ESC SAF EFF STUD

[10]

ClinicalTrials.gov, 2021, INTR ADM SCAAV9 JET

← 1 2 3 4 5 6 →